Skip to content
Polycystic Ovary Syndrome (PCOS) is one of the most common disorders, affecting 4 to 25% of women of reproductive age. In a study published in the journal Nutrients, the authors analyzed the effectiveness of alpha lipoic acid (ALA) in treating Polycystic Ovary Syndrome.
Understanding PCOS
In women with PCOS, numerous fluid-filled capsules, approximately 8 mm in size, form on the ovaries. These follicles containing immature egg cells are referred to as cysts. Often, these follicles fail to release mature eggs, resulting in a lack of ovulation.
PCOS has a complex etiology, with the vulnerability of each woman being influenced by various environmental and genetic risk factors, such as lifestyle and diet. The pathogenesis of PCOS can be significantly affected by oxidative stress, insulin resistance, and chronic inflammation.
For a more in-depth exploration of Polycystic Ovary Syndrome, including its causes, symptoms, complications, and treatments, refer to the article in our Encyclopedia.
Research Overview
Scientists analyzed 14 studies conducted between 2010 and 2022, primarily in Italy, for their current analysis. The aim was to determine the limitations and effectiveness of using alpha lipoic acid as an approach to treat PCOS. ALA is a natural substance with powerful antioxidant and anti-inflammatory properties. The studies explored various aspects, such as reducing androgen levels, improving reproductive outcomes, and decreasing insulin resistance in patients with PCOS.
What sets ALA apart is its unique dual solubility – it is both fat-soluble and water-soluble. Additionally, this substance can function in both the cytosol and cell membranes.
The Impact of Alpha Lipoic Acid on Patients with PCOS
Supplements of ALA have been found to reduce insulin resistance, particularly in patients with excess weight and type 2 diabetes. When combined with myoinositol (a natural substance from the B-vitamin group), ALA demonstrated even greater effectiveness in increasing insulin sensitivity. This combination also improved markers such as sex hormone-binding globulin (SHBG), androstenedione, free androgen index, DHEA-S, and anti-Müllerian hormone among women with PCOS.
Moreover, alpha lipoic acid enhanced the quality of oocytes in women undergoing in vitro fertilization (IVF) treatment.
It’s worth noting that the therapeutic effects were observed mainly in women with metabolic disorders. Therefore, further research is needed to fully understand the impact of ALA on PCOS therapy.
